- Home
- CPZ vs STRO Comparison
CPZ vs STRO Comparison
Compare CPZ & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- STRO
- Stock Information
- Founded
- CPZ 2019
- STRO 2003
- Country
- CPZ United States
- STRO United States
- Employees
- CPZ N/A
- STRO N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPZ Finance
- STRO Health Care
- Exchange
- CPZ Nasdaq
- STRO Nasdaq
- Market Cap
- CPZ 328.3M
- STRO 74.3M
- IPO Year
- CPZ N/A
- STRO 2018
- Fundamental
- Price
- CPZ $16.41
- STRO $0.89
- Analyst Decision
- CPZ
- STRO Hold
- Analyst Count
- CPZ 0
- STRO 7
- Target Price
- CPZ N/A
- STRO $1.97
- AVG Volume (30 Days)
- CPZ 63.0K
- STRO 598.8K
- Earning Date
- CPZ 01-01-0001
- STRO 11-12-2025
- Dividend Yield
- CPZ 11.07%
- STRO N/A
- EPS Growth
- CPZ N/A
- STRO N/A
- EPS
- CPZ N/A
- STRO N/A
- Revenue
- CPZ N/A
- STRO $104,473,000.00
- Revenue This Year
- CPZ N/A
- STRO $65.42
- Revenue Next Year
- CPZ N/A
- STRO N/A
- P/E Ratio
- CPZ N/A
- STRO N/A
- Revenue Growth
- CPZ N/A
- STRO N/A
- 52 Week Low
- CPZ $13.17
- STRO $0.52
- 52 Week High
- CPZ $16.11
- STRO $4.80
- Technical
- Relative Strength Index (RSI)
- CPZ 43.86
- STRO 48.54
- Support Level
- CPZ $16.58
- STRO $0.85
- Resistance Level
- CPZ $16.80
- STRO $1.01
- Average True Range (ATR)
- CPZ 0.15
- STRO 0.09
- MACD
- CPZ -0.02
- STRO -0.01
- Stochastic Oscillator
- CPZ 0.00
- STRO 16.63
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.